Aileron Therapeutics will hold a virtual event for KOL investors on May 19, 2022

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

BOSTON, May 13, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), an oncology chemoprotection company that aspires to make chemotherapy safer and therefore more effective in saving the lives of more patients, today announced that it will host a virtual KOL event for investors on Thursday, May 19, 2022 at 4:00 p.m. ET / 1:00 p.m. PT.

The virtual event will include presentations from the company’s President and CEO, Manuel Aivado, MD, Ph.D., as well as key opinion leaders, Ralf Paus, MD, DSc, FRSB, Professor of Dermatology, Dr. Phillip Frost’s Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine and Eric Anderson, MD, Ph.D., Medical Oncologist, Assistant Professor of Medicine, Oregon Health & Science University School of Medicine.

Presentations will highlight several topics related to the breakthrough potential of ALRN-6924 as the first supportive care drug based on precision medicine, as well as the current supportive care landscape and unmet needs associated with toxicities. induced by chemotherapy, including:

  • New non-clinical data that will be present in a late-breaking oral presentation at the Society for Clinical Dermatology 2022 Annual Meeting on May 19, 2022, demonstrating that ALRN-6924 protected human hair follicles and their stem cells against acute and permanent damage induced by chemotherapy;
  • An overview of Aileron’s randomized, double-blind, placebo-controlled Phase 1b clinical trial in patients with p53-mutated advanced non-small cell lung cancer, including the trial design and its composite endpoint;
  • An introduction to Aileron’s upcoming Phase 1b randomized clinical trial in patients with neoadjuvant breast cancer with p53 ER+/HER2- mutation, which is set to start in Q2 2022, and an update on the ongoing Phase 1 pharmacology study in healthy human volunteers; and
  • A review of the company’s planned data readings in 2022

A live webcast of the event will be available in the “Events & Presentations” section of the Investors & Media section of the Company’s website at A replay of the webcast will be available for 30 days after the presentation.

About Aileron Therapeutics
Aileron is a clinical-stage oncology chemoprotection company that aspires to make chemotherapy safer and therefore more effective in saving the lives of more patients. ALRN-6924, our first dual MDM2/MDMX inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only chemoprotective agent reported in clinical development to utilize a biomarker strategy, in which we focus exclusively on treating patients with p53-mutated cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells. As a result, healthy cells are spared from chemotherapy destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating the multiple side effects induced by chemotherapy, ALRN-6924 may improve patients’ quality of life and help them better tolerate chemotherapy. Better tolerance may lead to fewer dose reductions or chemotherapy delays and the potential for improved efficacy.

Forward-looking statements
The statements in this press release regarding Aileron’s future expectations, plans and outlook, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. of 1995. These statements include, but are not limited to, statements regarding the potential of ALRN-6924 as a chemoprotective agent, the Company’s strategy and clinical development plans. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, ” predict”, “project”, “should”, “target”, “should” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Actual results may differ materially from those indicated by these forward-looking statements due to various important factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the anticipated periods or with respect to anticipated matters; whether the initial results of clinical trials will be indicative of the final results of such trials or of results obtained in future clinical trials, including trials in different indications; whether ALRN-6924 will progress through the clinical trial process in a timely manner, or not at all; whether the results of such trials will be accepted and warrant submission for approval by the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether the ALRN-6924 will receive regulatory approval in a timely manner or at all or in what jurisdictions or indications the ALRN-6924 may receive approval; if, if ALRN-6924 obtains approval, it will be successfully distributed and marketed; what impact the coronavirus pandemic may have on the timing of our clinical development, clinical supply and operations; and other factors discussed in the “Risk Factors” section of Aileron’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed March 28, 2022, and risks described in other filings Aileron can do with securities and exchange commission. All forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. .